Patrick Gunning, Dunad's co-founder and acting CEO/CSO

No­var­tis en­lists transat­lantic start­up to dis­cov­er new pro­tein de­graders in $1.3B+ deal

With NI­BR chief Jay Brad­ner serv­ing as the in-house ex­pert on pro­tein degra­da­tion, No­var­tis has its stan­dards for the tech­nol­o­gy. A small transat­lantic start­up is clear­ly ready to meet them.

Dunad, a new play­er that emerged in the field in March, has scored a part­ner­ship with No­var­tis to de­vel­op what it calls next-gen­er­a­tion tar­get­ed pro­tein-de­grad­ing small mol­e­cule drugs. To kick things off, it’s get­ting $24 mil­lion in an up­front and eq­ui­ty in­vest­ment — plus “sig­nif­i­cant re­search fund­ing.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.